Erenumab-aooe for Temporomandibular Joint Disorder (TMD CARE Trial)

"Indeed, the information found on clinicaltrials.gov indicates that this experiment is actively enrolling volunteers. It was initially posted on April 1st 2022 and last updated May 4th 2022 with a target of 60 participants at one medical site."

"Amgen's Erenumab-aooe has been the subject of 18 live clinical trials in 32 countries and 179 cities since its Phase 3 approval trial, sponsored by Amgen, concluded with 456 participants back in 2019. Since then, an additional 18338 studies have been completed regarding this medication."

"Presently, 18 clinical trials are underway exploring the efficacy of Erenumab-aooe. Of those studies, 3 have advanced to the Phase 3 stage. While Rochester, Minnesota is home to many of these investigations, there are 549 other locations running experiments with this medication."

"Our assessment of erenumab-aooe's safety resulted in a score of 2, since there is current evidence attesting to its security but no established data on effectiveness."

"This medical trial is recruiting sixty individuals - aged 18 to 65 - with temporomandibular disorders. Other eligibility requirements for participation include: meeting two criteria concerning facial pain, consenting to the clinical trial, being compliant 80% of the time in their daily symptom diary within the baseline period and reporting an average pain level ≥30 on a numerical rating scale (0-100), discontinuing use of OTC medications prior to screening and baseline visit, allowing episodic or daily usage of short-acting non-prescription analgesics such as NSAIDs, acetaminophen, or aspirin during the study."

"According to clinicaltrials.gov, this medical study is actively recruiting patients. The trial began advertising on April 1st 2022 and the latest update was posted on May 4th 2022."

"The enrollment criteria for this trial necessitates that participants are of legal age and not yet retired."